“…Table 1 summarizes previously published studies reporting on the effect of the classical psychedelics psilocybin ( Meinhardt et al, 2020 ; Meinhardt et al, 2021 ), LSD ( Alper et al, 2018 ; Elsilä et al, 2022 ), ayahuasca ( Serra et al, 2022 ) or 2,5-dimethoxy-4-iodoamphetamine (DOI) ( Maurel et al, 1999a ; Maurel et al, 1999b ; Maurel et al, 2000 ; Oppong-Damoah et al, 2019 ; Berquist and Fantegrossi, 2021 ) on ethanol self-administration in animal models. The table also includes two serotonin 2A receptor (5-HT 2A R) agonist psychedelic analogs produced by rational pharmaceutical design; Tabernanthalog (TBG) ( Cameron et al, 2021 ), and (4-Bromo-3,6-dimethoxybenzocyclobuten-1-yl) methylamine hydrobromide (TCB-2) ( Kimmey et al, 2022 ). The administered classical psychedelic or 5-HT 2A R agonist psychedelic analog reduced ethanol consumption and/or preference in mice or rats in at least one experimental condition in all of these twelve studies, and the effect appeared dose-related in six of them ( Maurel et al, 1999a ; Maurel et al, 1999b ; Alper et al, 2018 ; Berquist and Fantegrossi, 2021 ; Elsilä et al, 2022 ; Kimmey et al, 2022 ).…”